S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:CGEM

Cullinan Oncology (CGEM) Stock Price, News & Analysis

$17.73
+0.95 (+5.66%)
(As of 03/27/2024 ET)
Today's Range
$16.69
$17.75
50-Day Range
$10.55
$19.02
52-Week Range
$7.64
$19.68
Volume
244,404 shs
Average Volume
472,774 shs
Market Capitalization
$763.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.67

Cullinan Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
61.7% Upside
$28.67 Price Target
Short Interest
Healthy
3.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of Cullinan Oncology in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.44 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.55) to ($3.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.71 out of 5 stars

Medical Sector

388th out of 939 stocks

Biological Products, Except Diagnostic Industry

59th out of 156 stocks

CGEM stock logo

About Cullinan Oncology Stock (NASDAQ:CGEM)

Cullinan Oncology, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CGEM Stock Price History

CGEM Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Cullinan Oncology: Q4 Earnings Insights
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Cullinan Oncology LLC (CGEM)
Recap: Cullinan Oncology Q3 Earnings
Cullinan Oncology Inc Ordinary Shares CGEM
See More Headlines
Receive CGEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CGEM
Fax
N/A
Employees
85
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.67
High Stock Price Target
$34.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+61.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-153,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$18.94 million
Book Value
$10.61 per share

Miscellaneous

Free Float
39,268,000
Market Cap
$763.63 million
Optionable
Optionable
Beta
0.34
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Nadim AhmedMr. Nadim Ahmed (Age 56)
    President, CEO & Director
    Comp: $1.16M
  • Mr. Jeffrey TrigilioMr. Jeffrey Trigilio (Age 40)
    CFO & Treasurer
    Comp: $922.61k
  • Dr. Jeffrey Jones M.B.A. (Age 53)
    M.D., M.P.H., Chief Medical Officer
    Comp: $780.32k
  • Dr. Patrick A. Baeuerle Ph.D. (Age 66)
    Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
    Comp: $763.73k
  • Dr. Jennifer Michaelson Ph.D. (Age 57)
    Chief Scientific Officer
  • Ms. Jacquelyn L. Sumer J.D. (Age 46)
    Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
  • Ms. Rose Weldon
    Senior Vice President of Communications
  • Mr. Steve Andre
    Chief Human Resources Officer
  • Dr. Corinne Savill Ph.D. (Age 65)
    Chief Business Officer
  • Mr. Kevin A. Johnston
    Chief Technical Operations Officer

CGEM Stock Analysis - Frequently Asked Questions

Should I buy or sell Cullinan Oncology stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGEM shares.
View CGEM analyst ratings
or view top-rated stocks.

What is Cullinan Oncology's stock price target for 2024?

4 brokers have issued 1-year price targets for Cullinan Oncology's stock. Their CGEM share price targets range from $22.00 to $34.00. On average, they expect the company's stock price to reach $28.67 in the next twelve months. This suggests a possible upside of 61.7% from the stock's current price.
View analysts price targets for CGEM
or view top-rated stocks among Wall Street analysts.

How have CGEM shares performed in 2024?

Cullinan Oncology's stock was trading at $10.19 on January 1st, 2024. Since then, CGEM shares have increased by 74.0% and is now trading at $17.73.
View the best growth stocks for 2024 here
.

Are investors shorting Cullinan Oncology?

Cullinan Oncology saw a increase in short interest in March. As of March 15th, there was short interest totaling 935,400 shares, an increase of 34.8% from the February 29th total of 694,100 shares. Based on an average daily volume of 402,300 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.6% of the shares of the company are short sold.
View Cullinan Oncology's Short Interest
.

When is Cullinan Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CGEM earnings forecast
.

How were Cullinan Oncology's earnings last quarter?

Cullinan Oncology, Inc. (NASDAQ:CGEM) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02.

When did Cullinan Oncology IPO?

Cullinan Oncology (CGEM) raised $149 million in an IPO on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

Who are Cullinan Oncology's major shareholders?

Cullinan Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Blue Owl Capital Holdings LP (7.99%), Franklin Resources Inc. (7.67%), Vanguard Group Inc. (4.14%), Vanguard Group Inc. (4.14%), Braidwell LP (2.90%) and American International Group Inc. (2.89%). Insiders that own company stock include Ansbert Gadicke, Bioscience I 2017 Ltd F2, Bvf Partners L P/Il, Corrine Savill, Jeffrey Alan Jones, Jeffrey Trigilio, Jennifer Michaelson, Leigh Zawel, Nadim Ahmed, Oncology Impact Fund LP Ubs and Vision Scs F2.
View institutional ownership trends
.

How do I buy shares of Cullinan Oncology?

Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGEM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners